Current clinical management of CIDP with immunoglobulins in France: An expert opinion

Elsevier

Available online 3 April 2023

Revue NeurologiqueAuthor links open overlay panel, , , , , , , , , , , , , , , , , , , Highlights•

Recurrent Ig shortages require a responsible use.

Disability and impairment scales should be used regularly to assess Ig efficacy.

Treatment dependence should be evaluated throughout treatment.

The minimum effective dose should be adjusted throughout the disease course.

Abstract

Treatment strategies in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) must be adapted on a case-to-case basis. Validated and reproducible tools for monitoring treatment response are required at diagnosis, when initiating treatment and throughout follow-up. A task force of French neurologists, experts in neuromuscular disease reference centers, was assembled to provide expert advice on the management of typical CIDP with intravenous immunoglobulins (Ig), and to harmonize treatment practices in public and private hospitals. The task force also referred to the practical experience of treating CIDP with Ig at the diagnostic, induction and follow-up stages, including the assessment and management of Ig dependence, and following the recommendations of the French health agency.

Keywords

CIDP

IVIg

Treatment

Maintenance

Efficacy criteria

MCIDs

AbbreviationsCIDP

chronic inflammatory demyelinating polyradiculoneuropathy

EAN

European Academy of Neurology

IVIg

intravenous immunoglobulin

INCAT

Inflammatory Neuropathy Cause and Treatment

MCID

minimum clinically important difference

MRC

Medical Research Council

PNDS

Protocole National de Diagnostic et de Soins (French national diagnosis and care protocol)

PNS

Peripheral Nerve Society

MCM

Multidisciplinary Consultation Meetings

R-ODS

Rasch-built Overall Disability Score

© 2023 The Authors. Published by Elsevier Masson SAS.

留言 (0)

沒有登入
gif